RecruitingNCT03647098
Survival Outcomes of Lung Cancer
Survival Outcomes for Lung Cancer
Sponsor
Hunan Province Tumor Hospital
Enrollment
20,000 participants
Start Date
Aug 1, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
This is a prospective study to analyze the survival outcomes of different groups about lung cancer patients.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This trial is collecting information about survival outcomes for patients with lung cancer who are receiving treatment, to better understand which factors and treatments lead to better results.
**You may be eligible if...**
- You are 18 years old or older
- You have been diagnosed with lung cancer confirmed by a biopsy or lab test
- You are in reasonably good physical condition (able to care for yourself and do light activity)
- Your expected survival is at least 12 weeks
- You have measurable cancer visible on imaging scans
- You have adequate blood counts and organ function
- You understand the study and are able to give informed consent
**You may NOT be eligible if...**
- You are unable to understand or agree to participate in the study
- You have very poor overall health
- You have had certain prior treatments that disqualify you per study criteria
- Your organ function (blood, liver, kidneys) is not adequate
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTreatment
Treatment decisions guided by molecular profiling and clinical judgment of principal investigators
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03647098
Related Trials
A Study of a Side Effects and Resource Navigation Program for People With Cancer
NCT076468478 locations
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828761 locations
Empathic Communication Skills (ECS) Training
NCT0545684112 locations
IDOV-Immune for Advanced Solid Tumors
NCT069106575 locations
A Registry for People With Lung Cancer
NCT0642432718 locations